STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)
Sponsor: Hoffmann-La Roche
A PHASE2 clinical study on Basal Cell Carcinoma, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 11 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Alcorcón, Spain , Ancona, Italy , Ankara, Turkey (Türkiye) , Arganda, Spain , Athens, Greece , Banja Luka, Bosnia and Herzegovina , Banská Bystrica, Slovakia , Barcelona, Spain , Barretos, Brazil and 150 more locations